Panitumumab-IRDye800

Phase 1

SStanford University

Panitumumab-IRDye800 is one of 33 therapeutic programs targeting Malignant Brain Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Malignant Brain NeoplasmRecruiting

Brain TumorRecruiting

MeningiomaRecruiting

PharynxNot yet recruiting

Malignant Brain NeoplasmPreclinical

Recruiting

Brain TumorPreclinical

Recruiting

MeningiomaPhase 1

Recruiting

PharynxPhase 1

Not yet recruiting

Competition

Competitive Landscape

27 competitors in Meningioma

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

2 2

Signifor

RRECORDATI GROUP

Approved

—3

Epsom Salt

FFresenius Kabi USA, LLC

Afinitor

2 5

Keytruda

Merck & Co.

Phase 2

2 6

Verzenio

Eli Lilly

Phase 2

1 7

Cabometyx

Bristol-Myers Squibb

Phase 2

1 8

Stivarga

Bayer

Phase 2

1 9

Lutathera

AAdvanced Accelerator Applications

Phase 2

1 10

Lutathera

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Malignant Brain Neoplasm

NCT03510208

Q4 2028

PreclinicalRecruiting

Brain Tumor

NCT04085887

Q2 2031

Phase 1Recruiting

Meningioma

NCT07493447

Q3 2031

Phase 1Not yet recruiting

Pharynx

NCT07741643

Clinical

Trials by Indication[1]

Pharynx1 trial

Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Not yet recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT07741643·30 enrolled

Meningioma1 trial

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Recruiting·EEben Rosenthal·Phase 1·NCT07493447·30 enrolled

Brain Tumor1 trial

Phase 1/Phase 2, Open Label Study Evaluating the Safety, Dosing and Efficacy of Panitumumab IRDye800 as an Optical Imaging Agent to Detect Pediatric Neoplasms During Neurosurgical Procedures

Recruiting·SStanford University·Preclinical·NCT04085887·12 enrolled

Malignant Brain Neoplasm1 trial

Phase I/II, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures

Recruiting·SStanford University·Preclinical·NCT03510208·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Panitumumab-IRDye800. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Panitumumab-IRDye800. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SStanford University

Panitumumab-IRDye800

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q2 2031

Q3 2031

Trials by Indication[1]

Pharynx1 trial

Meningioma1 trial

Brain Tumor1 trial

Malignant Brain Neoplasm1 trial

References

Drug Info

Quick Facts

Related News